Group tries to halt FDA regulation of lab-developed tests; Symbios smacked with Class I recall label;

 @FierceMedDev: Life Tech buys Korean distributor as Thermo waits. News | Follow @FierceMedDev

 @DamianFierce: Venture-backed Natera is expanding its prenatal test as it contends with $SQNM, $ILMN and others. Article | Follow @DamianFierce

 @MarkHFierce: Just met in Berlin with Christian Pangratz, CBO of Activaero, which has a promising drug-device liquid inhalation treatment for asthma. | Follow @MarkHFierce

 @MichaelGFierce: Chime in on the nano-gold discussion at the FierceBiotech LinkedIn page: Discussion | Follow @MichaelGFierce

> The American Clinical Laboratory Association is trying to stop the FDA's push to regulate laboratory-developed tests as medical devices. Story

> The FDA slapped a Class I recall status--its most serious label--on Symbios' GoPump Rapid Recovery System, a disposable pain-management device that includes a small balloon. Notice

> Amarantus Bioscience Holdings sealed a deal with BD Biosciences allowing BD to analyze samples for Amarantus' LymPro test for Alzheimer's disease. Item

> AngioScore won FDA approval of a PMA supplement labeling change, allowing the inclusion of a clinical trial results summary on its AngioSculpt PTCA Scoring Balloon angioplasty catheter's instructions for use. Item

> VentureHealth is rolling out an online equity crowdfunding platform for life sciences companies. Story

> Abyrx won FDA clearance for its new absorbable hemostatic bone putty, which comes ready-to-use. Item

> NASA launched a new funding program designed to spur healthcare/med tech entrepreneurs to develop healthcare products useable in space and on earth. Story

> Spectral MD is touting a new FDA 510(k) clearance for its DeepView medical imaging system, for studies of blood flow in microcirculation. Item

Biotech News

 @FierceBiotech: Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. Article | Follow @FierceBiotech

 @JohnCFierce: Royalty Pharma scrambles to salvage vote on hostile Elan takeover. Story | Follow @JohnCFierce

 @RyanMFierce: GSK has halted a study of an MS compound linked to data fraud in China. The plot thickens. More | Follow @RyanMFierce

 @EmilyMFierce: SCOTUS decision on Myriad case: Natural isolated DNA is not patentable. Synthetic DNA is patentable because it doesn't occur naturally. | Follow @EmilyMFierce

> Japanese biotech Prism snags $15M C round for cancer, fibrosis studies. News

> Lilly's oral rheumatoid arthritis blockbuster contender champions 1-year study. News

> Glaxo's dismissed China R&D chief fires back. Article

Pharma News

 @FiercePharma: Catalent kicks off $35M expansion in U.S. More | Follow @FiercePharma

 @EricPFierce: Novo suggests overzealous reading of risks of Type 2 diabetes drugs that include Victoza, Januvia. Article | Follow @EricPFierce

 @CarlyHFierce: Insider trading charges from Sanofi/Chattem deal continue to pile up. Brothers allegedly scored a $50k profit. Report | Follow @CarlyHFierce

> GSK probes sales tactics in China days after firing R&D chief there. More

> AARP fears Pfizer tactics to defend Lipitor could become model. Story

Pharma Manufacturing News

> Zydus recalls warfarin after oversized tablets discovered. Item

> FedEx vows not to settle with feds on online pharmacy shipments. Story

> FDA warning letter nails 2 Baxter plants for repeat violations. Article

> FDA comes down on another Indian drugmaker. Report

Vaccines News

> Latin American cancer vax races Big Pharma rivals. More

> FDA clears Sanofi to compete for 4-in-1 flu vaccine market. Report

> FDA setback sends Dynavax shares tumbling again. Article

> Oral vaccine aims to end dreaded Delhi belly. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.